Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
"Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes." JAMA Netw Open
In Pharmaceutical product development (Chapter 22)
[PMID: 30670548] PubMed record related to this compound for laboratory literature review
In the only reported trial to date involving people with AUD who actively wished to reduce or cease drinking, a once-weekly GLP-1 agonist called exenatide did not result, in the overall group, in a reduction of the number of heavy drinking days, but the drug did enable those with AUD and obesity to do so
US$ 25.57
US$ 20.56
US$ 25.45
US$ 27.19
US$ 20.52
